The ASCEND T1D Study is testing anti-thymocyte globulin (ATG) and teplizumab to compare their ability to delay the onset of type 1 diabetes (T1D) in people at high risk. A previous TrialNet study of teplizumab in people at high risk found it can delay clinical diagnosis...
TrialNet is studying rezpegaldesleukin to see if it can help the body continue making insulin in people newly diagnosed with type 1 diabetes (TID) by stimulating regulatory T cells to restore immune balance. Rezpegaldesleukin is already being studied in people with other autoimmune diseases like psoriasis...
[vc_row css_animation="" row_type="row" use_row_as_full_screen_section="no" type="full_width" angled_section="no" text_align="left" background_image_as_pattern="without_pattern"][vc_column][vc_column_text css=""] This study is looking at how an investigational study drug, called teplizumab, might possibly help protect insulin-producing cells by affecting the immune cells that attack them. The main goal of the study is to see if teplizumab...
The UW Medicine Diabetes Institute is the proud home of the COVERED Registry. COVERED stands for Community of Volunteers Engaged in Research to End Diabetes. The goal of this patient registry is to connect people interested in diabetes care with researchers studying diabetes and other...
[box class="summary"][/box]We are inviting you to participate in a research study to help us improve our understanding of diabetes and immune mediated diseases. The study consists of a computer registry where we store your contact, research, and health information, and a sample repository where we...
[box class="summary"][/box]Pathway to Prevention screening is the first step for all TrialNet prevention studies. Screening is offered at no cost to eligible individuals to evaluate their personal risk of developing the disease. This unique screening can identify the early stages of type 1 diabetes (T1D) years...
